ATG5 and breast cancer: In breast cancer, miR-567 could inhibit cancer cell proliferation and migration by regulating KPNA4 [21]; miR-567 could also regulate autophagy and reverse trastuzumab resistance via ATG5 in breast cancer [22]; in renal cell carcinoma, miR-567 could inhibit cancer cells progression by regulating PRDX3 [36].